Solriamfetol Gives Hope for Daytime Sleepiness in OSA Patients, Study Shows

A study showed that dopamine-norepinephrine reuptake inhibitor solriamfetol helps decrease excessive daytime sleepiness in patients with obstructive sleep apnea (OSA).


Photo: Obstructive Sleep Apnea (OSA) Patient | InStyleHealth


The research conducted randomized patients to receive 12 weeks of placebo or solriamfetol at 37.5, 75, 150, or 300 mg/day. Efficacy analysis was stratified by primary OSA therapy adherence. Coprimary endpoints were week-12 change from baseline in Maintenance of Wakefulness Test (40-minute MWT) and Epworth Sleepiness Scale (ESS).


There was a total of 324 (70.6%) participants were treatment adherent (continuous airway pressure usage >4hours/night on >70% nights, surgical intervention, or oral appliance use on >70% nights), and 135 (29.4%) of patients were nonadherent.


Comparing it with placebo, solriamfetol dramatically reduced excessive daytime sleepiness in patients. Average differences in MWT sleep latency with the 37.5, 75, 150, and 300-mg groups were 4.8, 8.4, 10.2, and 12.5 minutes respectively among the adherent patients, while 3.7, 9.9, 11.9 and 13.5 minutes among the nonadherent patients.


Meanwhile, mean differences in the ESS in 37.5, 75, 150, and 300-mg cohort versus the placebo group were -2.4, -1.3, -4.2, and -4.7 among the adherent patients, and -0.7, -2.6, -5.0, and -4.6 among the nonadherent patients separately.


However, prevalent reported adverse events or side effects included headache, nausea, anxiety, decreased appetite, nasopharyngitis, and diarrhea. Solriamfetol exerted no clinically changes in primary OSA therapy use according to the research study. For complete details of the study, click here.



Source: Chest 2021;doi:10.1016/j.chest.2021.02.033


If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post